Some medicines used for heart problems, like beta-blockers, ACE inhibitors, and calcium channel blockers, have been known to ...

Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ ...

Long-term treatment with ixekizumab does not increase the incidence of malignant neoplasms in patients with psoriasis, PsA, ...

This segment is sponsored by Arcutis Biotherapeutics.Nearly 9 million people in the U.S. have an inflammatory skin condition ...

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...

A new analysis highlights the effectiveness of risankizumab in patients with moderate plaque psoriasis and those newly classified as systemic therapy eligible under International Psoriasis Council ...

I use roflumilast for inverse psoriasis and tapinarof for thicker plaque psoriasis." Cheng said insurance considerations often come into play when deciding how to start psoriasis treatment.

Psoriasis and psoriatic arthritis (PsA) are both psoriatic diseases, which means they are related. Psoriasis increases your risk of PsA, but this doesn't mean you will get it.

Top-line results for the last cohort of patients in the Phase 2a clinical trial in mild-to-moderate psoriasis with SGX302 (synthetic hypericin) in 4Q 2025, where we have already demonstrated the ...

The researchers note that roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor, which targets inflammatory pathways central ...

Psoriasis is a chronic autoimmune condition that mainly affects the skin. When you have psoriasis, your immune system sends ...

Normally, skin cells take about a month to form and rise to the surface. In people with psoriasis, this process happens in ...